Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP943 | DOI: 10.1530/endoabs.49.EP943

ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (145 abstracts)

Success rates of pituitary surgery in acromegaly – a tertiary centre experience in Romania

Minodora Betivoiu 1 , Iulia Soare 1 , Sorina Martin 1, , Anca Sirbu 1, , Alice Albu 1, , Carmen Barbu 1, & Simona Fica 1,


1Endocrinology Department, Elias Hospital, Bucharest, Romania; 2Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.


Background: Pituitary surgery is the first treatment option for acromegaly. The reported success of pituitary surgery varies between 75 and 95% for microadenomas and 45 and 68% for macroadenomas. The aim of this study was to report our experience regarding the remission rate after pituitary surgery in acromegaly patients.

Methods: This retrospective study included 70 patients diagnosed with acromegaly in our clinic between 2009 and 2016. The criteria used to define remission were random GH <1 ng/ml and normalization of IGF1 levels for gender and age.

Results: 11 patients were lost of follow-up after the first diagnostic visit. We analysed 59 acromegaly patients (33 women and 26 men) with a mean age at diagnosis of 44.93±13.57 years. Microadenoms were found in 15 (25.4%) and macroadenomas in 44 (74.6%) patients. 6 (10.2%) patients associated both GH and prolactin hypersecretion. Pituitary surgery was performed in 41 patients of which 9 (21.4%) were cured. Aditional 7 (21.2%) patients were cured after second surgery and radiotherapy. Radiotherapy was the first treatment in 11 patients of which 3 (27.2%) were cured. Persistent disease after sugery and/or radiotherapy was treated with somatostatin analogs (26), dopamin agonists (18) and GH receptor bloacker (6) in mono or combination therapy.

Conclusions: The rate of surgical success in our patients was found to be low (40% for microadenomas, 6.8% for macroadenomas). This could be explained by the fact that most patients presented late at the macroadenoma stage.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.